Skip to main content
. 2007 Mar 27;98(5):652–658. doi: 10.1111/j.1349-7006.2007.00445.x

Figure 1.

Figure 1

Validation of the phosphorylated extracellular‐regulated kinase (p‐ERK1/2) antibody using western blot analysis. The endometrial epithelium‐derived cell line EM‐E6/E7/TERT was incubated with or without epidermal growth factor (EGF) at 10 or 100 nM for 15 min, and protein extracts were prepared and subjected to western blot analysis to assay expression of p‐ERK1/2. EM‐E6/E7/TERT cells transfected with oncogenic mutant KRAS were used as a positive control of p‐ERK1/2 expression. Two bands (42 and 44 kDa) were found to be induced by treatment with EGF or transfection with oncogenic mutant KRAS, and this effect was specifically inhibited by treatment with a MAP kinase‐ERK kinase (MEK) inhibitor (U0126), but not by a p38 (SB203580) or phosphatidylinositol‐3‐kinase (PI3K) inhibitor (Wortmannin). The expression levels of total ERK1/2 were not altered by these treatments.